Retapamulin
- Generic Name
- Retapamulin
- Brand Names
- Altabax
- Drug Type
- Small Molecule
- Chemical Formula
- C30H47NO4S
- CAS Number
- 224452-66-8
- Unique Ingredient Identifier
- 4MG6O8991R
- Background
Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
- Indication
For use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
- Associated Conditions
- Staphylococcal impetigo, Streptococcal impetigo
- Associated Therapies
- -
Retapamulin as a Decolonizing Agent for MRSA
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 47
- Registration Number
- NCT03304873
- Locations
- ๐บ๐ธ
New York University School of Medicine, New York, New York, United States
Retapamulin for Reducing MRSA Nasal Carriage
- Conditions
- Interventions
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 53
- Registration Number
- NCT01461668
- Locations
- ๐บ๐ธ
University of California, Irivne, Irvine, California, United States
United States Pharmacovigilence Retapamulin-Prescribing
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01153880
EU PV for Retapamulin-Prescribing
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01153828
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Ochsner Health System
- Registration Number
- NCT00856089
- Locations
- ๐บ๐ธ
Tulane University School of Medicine, New Orleans, Louisiana, United States
๐บ๐ธOchsner Health System, New Orleans, Louisiana, United States
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 57
- Registration Number
- NCT00539994
- Locations
- ๐บ๐ธ
GSK Investigational Site, Tacoma, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.